be turned in negative outcomes by the association with environmental risk factors, such as cannabis use. We focus our attention on aberrant salience, a peculiar psychotic experience, frequently reported during the prodromal phase that precede the onset of full-blown psychotic illness. Aberrant salience is the unusual or incorrect assignment of salience or significance to innocuous stimuli; it has been hypothesized to be an important mechanism in the development of psychosis. Methods: Undergraduate students of ULB (Universitè Libre de Bruxelles) and INSAS (Institut national supérieur des arts du spectacle) of Brussels (Belgium) were invited to participate to the study. A self-report questionnaire, investigating socio-demographic characteristics, and cannabis use was administered, evaluating lifetime and current cannabis use. Aberrant Salience Inventory (ASI) is a 29 item Yes-No questionnaire developed to evaluate aberrant salience. French version of Community Assessment of Psychic Experiences (CAPE), was used to evaluate dimensions of psychosis and PLEs. CAPE is a 42-item, self-report questionnaire, developed to measure the lifetime prevalence of PLEs in the general population. The questionnaire assesses three symptom dimensions (positive, depressive and negative symptoms). All statistical analysis was carried out with Statistical Package for Social Sciences, Version 20.0. We evaluated individual correlations between years of cannabis use and days of cannabis use in the last month with the tools scores. We also explored correlation of ASI score with different CAPE scores and different types of PLEs. Correlations were carried out by using the nonparametric Spearman correlation test. Results: The final sample was of 257 participants. 46,3% of subjects reported a lifetime cannabis use and 35.0% reported a current cannabis use (last 30 days). Compared with non-users, cannabis users showed significant higher ASI scores and also higher positive and negative dimensions CAPE scores. No significant association was found between cannabis consumption and the depressive dimension of CAPE. Years of cannabis use and frequency of use in the last 30 days showed a small positive correlation with ASI score; also, weaker positive correlations with CAPE positive and negative dimensions scores were observed. Discussion: To some extent, our results support the evidences that cannabis use is associated with an increased rate of psychotic experiences in individuals without clinical form of psychosis. Future prospective longitudinal studies are required to better investigate the meaning of the association between cannabis use and PLEs. Background: Acute cannabis use stimulates appetite, while general population studies suggest that chronic use is associated with reduced risk of obesity and other cardiometabolic risk factors. Methods: In this study, we investigated changes in body mass index (BMI), fasting blood glucose and lipids, and rates of metabolic syndrome risk factors in cannabis users vs. non-users in 109 minimally treated patients with first-episode schizophrenia, schizophreniform or schizo-affective disorder who were treated according to a standardized treatment regime with depot antipsychotic medication over 12 months. Participants underwent repeated urine toxicology tests
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Background: Cannabis has been associated with higher risk to develop psychosis and worse long-term outcomes. Cannabis use in 2016 is estimated to be 11.3% in Chile in 2016 (SENDA 2016). As in many other countries, cannabis use has steadily increased during last 20 years, across all socioeconomic groups, but especially in men and in the group aged 12 to 25 years old. At the same time, 5.7% subjects declared using high potency cannabis. We here examined the frequency of cannabis use in patients with a first episode psychosis in Chile. We also sought to identify etiologic factors associated with cannabis use, as well as its impact on clinical and functional status. Methods: We performed a cross-sectional study on patients from an outpatient Early Intervention in Psychosis unit in Chile. Data included sociodemographic characteristics, cannabis and other substance use, and standardized clinical and functional status. FAST (Functional Assessment Short Test), SS-DSM5 (Symptom Severity Scale of the DSM5 for Schizophrenia), CUPIT (Cannabis use Problem Identification Scale) and MG (Morinsky Green Adherence Questionnaire) were applied to the participants. Results: We included 80 patients, of which 23.8% used cannabis during the previous year. 47.3% of cannabis users had used cannabis with high THC concentration. 63.2% of consumers had a moderate-high score in the CUPIT scale, indicating a high prevalence of risk consumption and use disorder. Regarding variables related with cannabis use, correlation analysis showed a significant relationship with alcohol use (p<0.001), drug use (p<0.001) and duration of untreated psychosis (p=0.039, all corrected for multiple analysis.). Multivariate regression analyses including these variables along with gender and age, only showed relation with drug use (p=0.031, OR 7.94 (1.21-51.91). Regarding cannabis use and clinical and functional outcomes, correlation analysis showed association with adherence problems as reported by physician (p= 0.026) and the Morinsky Green Adherence Questionnaire (p= 0.031). Results showed an OR of 5.23 (1.38-19.76) for adherence problems and OR 0.2 (0.05-0.75) for Morinsky Green Adherence Questionnaire reporting good adherence. There was no effect in treatment resistance, FAST score, SS-DSM5 global, cognitive or negative score. Discussion: The percentage of cannabis use in this first episode psychosis sample is high, with a large subgroup using high potency THC cannabis. Cannabis use was associated to other drug use and to treatment adherence problems reported by physician and patient. This shows the importance of substance use treatment in first episode programs.
